77 results about "Leiomyocyte" patented technology

The invention belongs to the field of biological medicine, and particularly relates to application of deaminotyrosine in preparation of a medicine for treating vascular calcification symptoms. The invention finds that deaminotyrosine can significantly reduce the vascular calcification degree of an in-vitro cell model and an in-vivo animal model by inhibiting osteogenic differentiation and calcium salt deposition of vascular smooth muscle cells; therefore, the invention provides a new application of the deaminated tyrosine or pharmaceutically acceptable salt, ester, solvate or prodrug thereof in preparation of drugs for treating vascular calcification symptoms. The invention also provides a pharmaceutical composition, which takes deaminated tyrosine as an active component, and provides a brand new drug choice for clinical prevention and treatment of vascular calcification.

The invention discloses a functional coating, an intravascular stent and a preparation method and application of the intravascular stent. The functional coating comprises an endothelialization promoting active substance and an anti-proliferation drug; the endothelialization promoting active substance comprises at least one of polypeptide containing an RGD sequence, polypeptide containing a YIGSR sequence, polypeptide containing an REDV sequence, a beta-polypeptide polymer or a beta-polypeptide-polyester block copolymer. The functional coating disclosed by the invention can be used for surface functional modification of interventional medical devices, can selectively promote adhesion and proliferation of vascular endothelial cells at an implantation part, realizes rapid endothelialization, and can controllably release an anti-proliferation drug to inhibit excessive proliferation of vascular smooth muscle cells, so that the vascular endothelial cells are prevented from being damaged. Therefore, the risks of restenosis and advanced thrombus are effectively reduced.

The invention discloses application of gynostemma pentaphyllum polysaccharide to prevention of vascular wall thickening caused by space microgravity and a medicine, the gynostemma pentaphyllum polysaccharide is applied to prevention of vascular wall thickening caused by space microgravity and the medicine for prevention of vascular wall thickening caused by space microgravity, and the medicine contains the gynostemma pentaphyllum polysaccharide; the gynostemma pentaphyllum polysaccharide reduces thickening of blood vessel walls by inhibiting proliferation and migration of vascular smooth muscle cells, can be used for preventing or treating aorta blood vessel wall thickening caused by space microgravity, and is suitable for health guarantee of astronauts in long-term space missions.

The invention belongs to the technical field of artery stents, and particularly relates to a degradable coronary artery stent and a preparation method thereof. Wherein the degradable coronary stent is of a tubular network structure prepared by a main frame and connecting rib components, the main frame is of an open network structure, anchoring points are arranged at nodes, and the connecting rib components are detachably connected and lock the main frame through the anchoring points to form an integral rigid structure, so that the elastic retraction force after a blood vessel is implanted is effectively resisted; the connecting rib component is gradually degraded and loses the locking capacity along with the promotion of vascular repair, the loaded rapamycin is synchronously released, smooth muscle cells with active proliferation are accurately inhibited, the risk of restenosis in the stent is reduced, meanwhile, the activity of the main framework is recovered, the main framework slightly deforms along with vascular pulsation, and vascular intimal injury and inflammatory response are reduced.

The application relates to the application of lycorine hydrochloride in the preparation of a medicine for inhibiting the proliferation of a neointimal in a blood vessel. Lycorine hydrochloride has the effect of inhibiting the proliferation of a neointimal in a blood vessel, and the effect is mainly realized by inhibiting the proliferation and migration of vascular smooth muscle cells. In the body, the results show that lycorine hydrochloride can significantly inhibit the intimal proliferation caused by left common carotid artery ligation, and in vitro experiments prove that lycorine hydrochloride can intervene in the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB. Lycorine hydrochloride inhibits the proliferation, migration and phenotype transformation of VSMCs induced by PDGF-BB, and the proliferation of a neointimal in a blood vessel through a MAPKs signal path. The application provides data for preparing lycorine hydrochloride into a medicine for inhibiting the proliferation of a neointimal in a blood vessel, and is expected to be applied to the prevention and treatment of complications after percutaneous coronary intervention, such as restenosis or in-stent thrombosis, and can become a potential medicine for intervening in restenosis.

The invention relates to the technical field of biomedical materials. The invention discloses a Schiff base-sulfonated hyaluronic acid light-cured microsphere as well as a preparation method and application thereof. The microspheres are prepared by condensing DL-lysine and paeonol to generate Schiff base, then conjugating the Schiff base with sulfonated hyaluronic acid through a carbodiimide chemical method, and finally molding by adopting a microfluidic technology and carrying out ultraviolet curing. The metal chelation characteristic of Schiff base is combined with the precise structure regulation advantage of the microspheres, and the prepared microspheres show an excellent synergistic effect when applied to the surfaces of implant materials such as degradable magnesium alloy, iron alloy and zinc alloy: the corrosion resistance of a base material can be remarkably improved, an effective protective layer is formed, and the service life of the microspheres is prolonged. Meanwhile, the compound has multiple biological functions of promoting endothelial cell proliferation, inhibiting excessive proliferation of smooth muscle cells and regulating and controlling macrophages to be polarized to anti-inflammatory phenotypes, and has a wide application prospect in the biomedical fields of intravascular stents, bone fixing instruments and the like.

An artificial tissue tube having a stem cell-derived smooth muscle layer and an endothelial cell layer is produced. Compared with conventional methods, it is possible to produce an artificial tissue tube that produces physiological contraction and relaxation reactions by using at least three times of stem cell-derived smooth muscle cells and further using stem cell-derived endothelial cells to produce an artificial tissue tube. An artificial blood vessel produced using an iPS cell derived from a patient with Viller's syndrome is shown to be an artificial blood vessel reflecting a pathological condition, and therefore an artificial tissue tube reflecting a pathological condition of a plurality of diseases can be produced using the iPS cell. The artificial tissue tube can be used for screening and transplanting medicines.

The invention discloses a composite medicine coating for treating pulmonary arterial hypertension, and belongs to the technical field of medical instruments. The coating is composed of an inert protective layer and a composite drug coating, the inert protective layer is a polyamino acid polymer, responds to pH change and is rapidly disintegrated only in the pH environment of a target site, and the loss of the composite drug coating in the delivery process is reduced; the composite drug coating is a composite component containing two or more gene regulatory factors and / or drugs, achieves a synergistic effect through a signal path, cells and a gene level, more efficiently regulates pulmonary artery endothelial cell dysfunction and smooth muscle cell injury, and has precise targeting and irreplaceability.

The invention discloses application of icariin in preparation of drugs for preventing and treating chronic kidney disease mineral substances and bone metabolism disorders. Relates to the technical field of medicine. The invention provides an application of icariin as an active pharmaceutical ingredient in preparation of a CKD-MBD treatment drug. Pharmacological experiments show that icariin can improve renal fibrosis, inhibit hyperparathyroidism, correct calcium and phosphorus metabolism, regulate and control bone metabolism related molecular expression, inhibit transdifferentiation of vascular smooth muscle cells to bone cells, inhibit vascular calcification and correct bone metabolism disorder, so that CKD-MBD is effectively prevented and treated. When icariin is used for preventing or treating CKD-MBD, the icariin is clear in component, exact in curative effect and low in side effect, and has a wide medical application prospect.

The invention relates to application of harmine in preparation of a medicine for preventing and treating vascular calcification. The harmine can be used for preventing and / or treating vascular calcification. Experiments show that harmine reduces osteogenic differentiation of vascular smooth muscle cells by down-regulating expression of RUNX2 and BMP2 and up-regulating expression of alpha-SMA at the same time, calcium salt deposition of blood vessels can be reduced, and it is indicated that harmine has a remarkable inhibition effect on vascular calcification. The new application of harmine in the anti-vascular calcification aspect is confirmed, so that the research of harmine in the technical field of medicines can be expanded, a new way is provided for research and development of drugs for treating vascular calcification, and a new theoretical direction is provided for clinical application.

The present application relates to the application of delta-Viniferin in the preparation of drugs for preventing or treating metabolic cardiovascular diseases. Delta-Viniferin can inhibit the expression level of aging and inflammation related genes / proteins of vascular endothelial cells, reduce endothelial dysfunction, and clarify its anti-hypertensive effect. Delta-Viniferin can inhibit the expression level of vascular smooth muscle cell phenotype conversion related genes / proteins, improve the contraction function of vascular smooth muscle, and significantly alleviate the degradation of elastic fibers of the vascular wall and the rupture of the intima of the aortic wall in vivo, and clarify its effect on preventing and treating aortic dissection. Delta-Viniferin can inhibit the expression level of myocardial fibroblast fibrosis related genes / proteins, and clarify its anti-myocardial fibrosis effect. Delta-Viniferin can promote white adipose tissue browning by targeting the SIRT1-FOXO1 axis, increase energy consumption, and clarify its effect on resisting obesity. In summary, the compound delta-Viniferin has the effect of protecting various metabolic cardiovascular diseases, and can be used to prepare drugs for preventing and treating metabolic cardiovascular diseases.

The invention provides application of a mucolipoprotein transient receptor potential channel 1 as a target spot in preparation of a medicine for treating pulmonary arterial hypertension, and belongs to the technical field of biological medicine manufacturing. The invention relates to application of a mucolipoprotein transient receptor potential channel 1 (TRRP Mucipin1, TRPML1) as a target spot in preparation, development or screening of a medicine for treating pulmonary hypertension (PH), in particular to application of the medicine in preparation, development or screening of the medicine for treating the PH. The invention also provides application of a reagent 1 for up-regulating smooth muscle cell Mcoln1 gene and / or smooth muscle cell TRPML1 protein expression or a reagent 2 for improving smooth muscle cell TRPML1 protein activity in preparation of drugs for treating PH. Experiments show that the over-expressed TRPML1 in the smooth muscle affects the PH pulmonary vascular remodeling process and PH generation and development through autophagy regulation and control, and the purpose of PH treatment is achieved.

The invention relates to the technical field of molecular biology and medicine, and particularly discloses application of WWP1 in preparation of a medicine for preventing and / or treating aortic dissection, and relates to application of WWP1 in prevention and treatment of aortic dissection. Molecular biology experiment detection of the expression level of the WWP1 in aortic dissection aortic tissue and the expression level of smooth muscle cell contraction and secretion phenotype marker genes proves that the expression level of the WWP1 in an aortic dissection aortic tissue sample is obviously higher than that of a control aortic tissue; and overexpression of the WWP1 in an animal model significantly reduces the morbidity of the aortic dissection and improves the contraction phenotype of the aortic smooth muscle, i.e., the protectiveness of the WWP1 in the morbidity process of the aortic dissection is improved. Based on the research result, the WWP1 can be used as a drug target for screening, preventing and treating the aortic dissection.

The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment of age-related diseases. It has been found that inhibition of Cbfβ expression in vascular smooth muscle cells promotes vascular calcification and osteoclast differentiation and that the culture fluid of Cbfβ-expressing vascular smooth muscle cells inhibits osteoclast differentiation. Thus, the composition can be advantageously utilized as a pharmaceutical composition for the prevention, treatment, alleviation, or diagnosis of age-related diseases.

The invention discloses a multifunctional intravascular stent for diabetics and a preparation method of the multifunctional intravascular stent, and relates to the technical field of cardiovascular interventional therapy instruments. The polycitrate is used as a carrier on the surface of the intravascular stent body to form the drug-loaded slow-release coating, and the drug-loaded slow-release coating has high antioxidant content, can provide oxidative stress attenuation continuously for a long time, provides a good microenvironment for cell tissue recovery, and promotes regeneration and repair of blood vessels. The biological immunosuppressor and the diabetes specific drug are loaded in the drug-loaded slow-release coating, the biological immunosuppressor is a drug having an excellent effect on common patients, the diabetes specific drug is a drug having a specific effect on diabetic patients, and the two drugs have a synergistic effect, so that the effect of treating diabetes is achieved; the coating on the surface of the intravascular stent has the effects of resisting inflammation, improving endothelial dysfunction and inhibiting proliferation and migration of smooth muscle cells aiming at diabetic patients so as to promote regeneration and repair of diseased blood vessels of the diabetic patients.

The present application belongs to the technical field of biomedical functional materials, and particularly relates to a multifunctional drug structure coating with regulation of lesion microenvironment homeostasis and a preparation method thereof. The nano drug carrier can load drugs with anti-smooth muscle cell growth or regulation of inflammation, the drugs can resist the growth of smooth muscle cells or regulate microenvironment inflammation, and provide a stable and safe microenvironment for the adhesion and growth of endothelial cells. Under the action of an oxidizing agent, polyphenol and polyamine compounds undergo oxidation, crosslinking and polymerization reactions, and a polyphenol nanoparticle (10 nanometer level) film layer is generated outside the nano drug carrier (100 nanometer level). The polyphenol nanoparticle film layer not only serves as a protective layer for the nano drug carrier and crosslinking substances therebetween, but also can fix the nano drug carrier on the surface of a base material, and together with the drug carrier, a drug structure coating with a topological structure is constructed. The hydrophilic groups contained in the coating make the surface super-hydrophilic and negatively charged.

The invention discloses application of an extracellular matrix in preparation of an anti-vascular aging product, and belongs to the field of biological medicine. The acellular extracellular matrix provided by the invention is prepared by taking umbilical artery vascular smooth muscle cells as a material and carrying out water swelling and 0.5% Triton X-100 treatment on the umbilical artery vascular smooth muscle cells. The invention also provides application of the acellular matrix in preparation of drugs for inhibiting blood vessel and cell senescence. Experimental results show that after aortic vascular smooth muscle cells overexpressing Pelamin A are inoculated to the acellular matrix and cultured, the aortic vascular smooth muscle cells are distributed in a concentrated manner, the number of the aortic vascular smooth muscle cells is increased, the form of the aortic vascular smooth muscle cells is remarkably improved, the expression of X-GAL in the cells is reduced, and the expression quantity of Ki67 is increased; therefore, the acellular extracellular matrix provided by the invention can be used for effectively regulating aortic vascular smooth muscle cell senescence induced by Pelamin A accumulation. The invention provides a new biological material for inhibiting vascular aging and cell aging.

The application relates to the application of YAP protein in the proliferation or apoptosis of vascular smooth muscle cells under the stimulation of mechanical stress. The application relates to the correlation research of YAP protein and the Hippo pathway, and also relates to YAP inhibitors including siRNA and shRNA. After the vascular smooth muscle cells are transfected by the YAP inhibitors (siRNA and shRNA), the expression of YAP is knocked down. When YAP is knocked down, the cell proliferation of the vascular smooth muscle cells under the stimulation of mechanical stress is inhibited. The application opens up a new research prospect for the treatment of blood diseases, and provides a new idea for the deep development of the YAP inhibitors and the clinical treatment of blood diseases.

The present inventions is to produce a tissue engineered tube including a smooth muscle layer and an endothelial cell layer derived from stem cells. It is possible to produce a tissue engineered tube that generates physiological contraction and relaxation reactions by producing a tissue engineered tube using smooth muscle cells derived from stem cells at least three times or more as those used in a method of the related art, and using endothelial cells derived from stem cells. Since an artificial blood vessel produced using iPS cells derived from a Werner syndrome patient indicates being an artificial blood vessel reflecting a pathological condition, tissue engineered tubes reflecting pathological conditions of various diseases can be produced using iPS cells. The tissue engineered tube can be used in pharmaceutical screening and transplantation.

The invention relates to the field of biological manufacturing and tissue engineering, and particularly discloses a multi-biological-structure-feature artificial blood vessel manufacturing method which comprises the steps that a parameterized model of an artificial blood vessel is constructed, and the model defines multi-layer biological structure features of the blood vessel and defines the corresponding relation between the multi-layer biological structure features and a printing path; a G code for controlling cross-scale radial 3D printing is generated based on a model, and through the same rotating shaft receiving device and linkage control, integrated manufacturing of a macroscopic layered structure and a microcosmic fiber network structure is achieved in the one-time forming process. Wherein the inner elastic film and the outer elastic film with the corrugation mechanical property are accurately formed by combining unstable state coaxial extrusion with a grid type tight path; millimeter-scale fibers loaded with smooth muscle cells are stacked through a spiral large-lead path, and a middle membrane with a contraction function is constructed; a nanoscale fiber network is constructed through grid type macroscopic near-field direct-writing electrostatic spinning, and a bionic outer membrane is formed to promote cell adhesion.

Disclosed herein are internal anal sphincter constructs, and methods for generating and / or using such constructs. Also provided herein are methods for using internal anal sphincter construct(s) for treating fecal incontinence in a subject. The method of generating an innervated internal anal sphincter construct, provided herein, comprises using smooth muscle cells (SMCs) from an anorectum tissue cell biopsy and neural progenitor cells (NPCs) from an intestinal tissue cell biopsy from the subject.

The application provides application of a SIRT6 activator as an active ingredient in preparation of a medicament for treating and preventing a blood vessel aging related disease. Application of the SIRT6 activator in a blood vessel smooth muscle cell can significantly inhibit aging of the blood vessel smooth muscle cell and increase of an aging related inflammatory factor. In a mouse thoracic aortic aneurysm model constructed by a CaCl2 incubation method, application of the SIRT6 activator can obviously inhibit an aneurysm phenotype.

The vasculopathy of hyperglycemia is a common and highly harmful complication of diabetes mellitus, and is characterized by abnormal accumulation of vascular smooth muscle cells (VSMCs) in vascular intima and media due to excessive proliferation and reduction of apoptosis of the VSMCs. This proliferation and apoptosis imbalance of VSMCs is considered to be likely to play a key role in the pathogenesis and progression of diabetic vascular complications. According to the invention, the cyclopeptide COX52-69 is found to be capable of directly inhibiting proliferation and migration of smooth muscle cells induced by high glucose. The evidence of the cyclopeptide is that in CCK8 cell proliferation detection and cell migration experiments, we find that the cyclopeptide can significantly inhibit abnormal proliferation and migration of high-glucose-induced smooth muscle cells, while the cyclopeptide with the same concentration acts on high-glucose-induced HEK293T cells to perform CCK8 cell proliferation detection. However, the cyclopeptide is found to have no influence on proliferation of HEK293T cells in high glucose (no promotion or inhibition effect). Therefore, the peptide has targeting specificity on the inhibition effect on proliferation and migration of high-glucose-induced smooth muscle cells, and also has certain biological safety. High glucose-induced proliferation and migration of smooth muscle cells are main causes of diabetic vasculopathy, so that the peptide can be used for complications caused by the diabetic vasculopathy. A new hope is brought to intervention of diabetic complications.

The application discloses a kind of small-bore tissue engineering blood vessel construction methods and artificial blood vessel.The construction method includes: obtaining ex vivo vascular smooth muscle cells and preparing it into cell suspension;The cell suspension is inoculated on artificial blood vessel support and is carried out segmented culture, and the segmented culture includes: first-stage culture, second-stage culture, third-stage culture;The first-stage culture uses first culture medium;The second-stage culture uses second culture medium;The third-stage culture uses third culture medium;The construction method provided by the application has the advantages of simple equipment, low cost, convenient operation, can realize high-throughput parallel culture and significantly shorten the culture cycle, provides efficient, feasible new scheme for the scale preparation and clinical application of small-bore tissue engineering blood vessel.

The application belongs to the field of medicine and relates to application of TTK gene and TTK inhibitor in treating restenosis after blood vessel injury. The application establishes a mouse blood vessel injury model to simulate the process of restenosis after blood vessel injury, detects the blood vessel remodeling of the mouse, and detects the expression of smooth muscle cell contraction phenotype marker, and the results show that inhibiting TTK gene has the effects of inhibiting smooth muscle cell phenotype conversion and inhibiting blood vessel remodeling after blood vessel injury to cause lumen stenosis. This indicates the function of TTK gene in restenosis after blood vessel injury, mainly that TTK gene has the functions of promoting smooth muscle cell phenotype conversion and blood vessel remodeling to cause lumen stenosis. In view of the above functions of TTK, TTK can be used as a drug target for screening drugs for treating blood vessel stenosis diseases, and the TTK inhibitor can be used for preparing drugs for preventing and treating restenosis after blood vessel injury.

The invention discloses an application of a gene for coding LRP1-beta chain oligopeptide as a target in screening / preparing a medicine for treating aortic dissection, an application of a reagent for inducing overexpression of the LRP1-beta chain oligopeptide in preparing the medicine for treating the aortic dissection, and an application of the LRP1-beta chain oligopeptide as a biomarker in preparing an aortic dissection diagnostic reagent. Experiments prove for the first time that the LRP1-beta chain oligopeptide can inhibit phenotypic transformation of vascular smooth muscle cells and inflammatory infiltration of macrophages by down-regulating expression of OPN, alleviate inflammatory response and relieve or inhibit occurrence and development of aortic dissection, provides a new direction and thought for treatment of aortic dissection, and has broad application prospects in treatment of aortic dissection. The compound is expected to be applied to research and development of new drugs for treating aortic dissection

The invention discloses a piezoelectric composite intravascular stent and a preparation method and application thereof, and belongs to the technical field of biomedical materials and medical instruments.The piezoelectric composite intravascular stent comprises a stent body, and the stent body is of a tubular structure formed by weaving piezoelectric composite fibers; the piezoelectric composite fiber comprises a substrate material and a piezoelectric enhancement component, the substrate material comprises a fluorine polymer piezoelectric material, the piezoelectric enhancement component is lead-free piezoelectric ceramic nanoparticles, and the lead-free piezoelectric ceramic nanoparticles comprise at least one of barium titanate, potassium niobate and zinc oxide. The mass ratio of the lead-free piezoelectric ceramic nanoparticles in the piezoelectric composite fiber is 1%-10%; the stent body can generate output voltage of 50mV-100mV under the action of blood flow shearing force, and is used for promoting vascular endothelial repair and inhibiting proliferation and migration of vascular smooth muscle cells. The problems that a traditional intravascular stent cannot regulate and control the vascular repair process through electrical stimulation, application of existing piezoelectric materials cannot meet the characteristic requirements of the intravascular stent, and then postoperative intravascular restenosis is difficult to prevent and treat can be solved.

The application belongs to the technical field of biological medicine, and particularly relates to a pharmaceutical use of a Hedgehog pathway inhibitor in preventing and treating vascular remodeling and restenosis after an arterial bypass operation and improving the survival rate of a coronary heart disease patient after the arterial bypass operation. The abnormal proliferation of smooth muscle cells driven by endothelial cell activation can be obviously inhibited by the Hedgehog pathway inhibitor GDC-0449 intervention, and the inflammatory reaction can be effectively reduced. In the in-vivo experiment, the local application of GDC-0449 to the bypass artery can significantly relieve the remodeling and stenosis of the bypass artery, and provide a theoretical basis and strong support for the molecular targeted treatment strategy of the vascular remodeling and failure after the arterial bypass operation.

The invention relates to application of an Arteridin gene as a biomarker in preparation of a product for auxiliary diagnosis of abdominal aortic aneurysm, clinical specimens and animal experiments find that the expression of Arteridin in occurrence of abdominal aortic aneurysm is remarkably increased, which indicates that Arteridin can be used as the biomarker for auxiliary diagnosis of abdominal aortic aneurysm; the invention also relates to a product for down-regulating the expression of Arterin and an application of the product in preparation of drugs for treating abdominal aortic aneurysm, the product comprises siRNA and shRNA of a targeted Arterin gene and AAV for coding the sequence of the shRNA, and after specific knockdown of Arterin by smooth muscle cells is realized, in an Elatase-induced abdominal aortic mouse model, the expression of Arterin is reduced, and the expression of Arterin is reduced. The diameter of the aneurysm is reduced, the occurrence rate is reduced, the elastin destruction degree is reduced, the expression quantity of vascular remodeling genes MMP2 and MMP9 is reduced, and the difference is obvious compared with that of a control group; the result shows that Arteridin is expected to become a target spot for treating abdominal aortic aneurysm.